Melanoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Melanoma – Pipeline Review, H1 2017’, provides an overview of the Melanoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Melanoma

The report reviews pipeline therapeutics for Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Melanoma therapeutics and enlists all their major and minor projects

The report assesses Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Melanoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Melanoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P-Pharma SAS

4SC AG

AB Science SA

AbbVie Inc

Abivax SA

Adaptimmune Therapeutics Plc

Aduro BioTech Inc

Advanced Cancer Therapeutics LLC

Affichem SA

Agenus Inc

AGV Discovery SAS

AIMM Therapeutics BV

Alethia Biotherapeutics Inc

Alkermes Plc

Altor BioScience Corp

Amgen Inc

Anavex Life Sciences Corp

Angimmune LLC

Antibe Therapeutics Inc

Antigen Express Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Apogenix GmbH

Aposense Ltd

Aptose Biosciences Inc

ARMO Biosciences Inc

Array BioPharma Inc

Asana BioSciences LLC

Astellas Pharma Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Autotelic Inc

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bayer AG

BeiGene (Beijing) Co Ltd

Beijing Kawin Technology Share-Holding Co Ltd

Bellicum Pharmaceuticals Inc

BerGenBio ASA

Bio-Cancer Treatment International Ltd

Biocad

Biogazelle NV

BioLineRx Ltd

Bioncotech Therapeutics SL

Bionomics Ltd

BioNTech AG

Biothera Pharmaceutical Inc

Biovista Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Company

Calithera Biosciences Inc

Can-Fite BioPharma Ltd

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Celprogen Inc

Celyad SA

Checkmate Pharmaceuticals Inc

Chipscreen Biosciences Ltd

Chugai Pharmaceutical Co Ltd

Cipher Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

CytomX Therapeutics Inc

Cytori Therapeutics Inc

Cytune Pharma SAS

CyTuVax BV

CZ BioMed Corp

Daiichi Sankyo Company Ltd

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

Dicerna Pharmaceuticals Inc

Dynavax Technologies Corp

Eisai Co Ltd

Eli Lilly and Company

Elsalys Biotech SAS

Ensol Biosciences Inc

EntreChem SL

eTheRNA Immunotherapies NV

Exelixis Inc

Exicure Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Galapagos NV

Galectin Therapeutics Inc

Genelux Corp

Genocea Biosciences Inc

Genzyme Corp

GlaxoSmithKline Plc

Gradalis Inc

GreenPeptide Co Ltd

Hadasit Medical Research Services & Development Ltd

Hanmi Pharmaceuticals Co Ltd

Heat Biologics Inc

Hemispherx Biopharma Inc

Histogen Inc

HitGen LTD

Horizon Pharma Plc

Humorigin Biotechnology Corp

Idera Pharmaceuticals Inc

Ignyta Inc

Immodulon Therapeutics Ltd

Immune Design Corp

Immune Response BioPharma Inc

ImmunGene Inc

Immunocore Ltd

ImmunoGen Inc

Immupharma Plc

IMPACT Therapeutics Inc

Imugene Ltd

Incyte Corp

Infinity Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

InteRNA Technologies BV

Intezyne Technologies Inc

IO Biotech ApS

JHL Biotech Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

K-Stemcell Co Ltd

KaloBios Pharmaceuticals Inc

Kancera AB

Karyopharm Therapeutics Inc

Kite Pharma Inc

Leap Therapeutics Inc

Lentigen Technology Inc

Lindis Biotech GmbH

Lion Biotechnologies Inc

Lipotek Pty Ltd

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Lupin Ltd

Lytix Biopharma AS

MabVax Therapeutics Holdings Inc

MacroGenics Inc

Magnus Life Ltd

MaxiVAX SA

MediaPharma Srl

Medicenna Therapeutics Corp

MedImmune LLC

MELEMA Pharma GmbH

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

Molecular Templates Inc

Moleculin Biotech Inc

Morphotek Inc

NantKwest Inc

Nektar Therapeutics

Neonc Technologies Inc

Nerviano Medical Sciences Srl

Neumedicines Inc

NewLink Genetics Corp

NormOxys Inc

Northwest Biotherapeutics Inc

Novartis AG

Novogen Ltd

Omeros Corp

Oncology Research International Ltd

Oncolys BioPharma Inc

Oncolytics Biotech Inc

OncoNOx ApS

OncoSec Medical Inc

OncoTartis Inc

Oncovir Inc

Onxeo SA

Opsona Therapeutics Ltd

Orega Biotech SAS

OSE Immunotherapeutics

Pacific Northwest Biotechnology LLC

Patrys Ltd

PepVax Inc

Peregrine Pharmaceuticals Inc

Pfizer Inc

Pharmicell Co Ltd

Pharminox Ltd

Pharmis Biofarmaceutica Lda

Philogen SpA

PinCell srl

Pivotal BioSciences Inc

Plexxikon Inc

Polaris Pharmaceuticals Inc

Polyplus-Transfection SA

Prima BioMed Ltd

Primevax Immuno Oncology Inc

Propanac Biopharma Inc

Provectus Biopharmaceuticals Inc

Provenance Biopharmaceuticals Corp

Qu Biologics Inc

Rafael Pharmaceuticals Inc

Reata Pharmaceuticals Inc

Recepta Biopharma SA

Recombio SL

Regeneron Pharmaceuticals Inc

Rexahn Pharmaceuticals Inc

Rgenix Inc

Rubicon Biotechnology Inc

RXi Pharmaceuticals Corp

Sanofi

SATT North SAS

Scancell Holdings Plc

SilaGene Inc

Sillajen Biotherapeutics

SolaranRx Inc

Sorrento Therapeutics Inc

Spotlight Innovation Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Susavion Biosciences Inc

SuviCa Inc

Syndax Pharmaceuticals Inc

Synthon Holdings BV

Syntrix Biosystems Inc

Tactiva Therapeutics LLC

Taiga Biotechnologies Inc

Taiwan Liposome Company Ltd

Takara Bio Inc

Takeda Pharmaceutical Company Ltd

Takis Srl

Targovax ASA

TC BioPharm Ltd

Theravectys SA

Tikcro Technologies Ltd

TILT Biotherapeutics Ltd

Tiltan Pharma Ltd

Tocagen Inc

TREAT U SA

TVAX Biomedical Inc

UbiVac LLC

Ultimovacs AS

UNC Health Care

Vaccibody AS

Vascular Biogenics Ltd

Vault Pharma Inc

Vaxenta Biotechnologies

Vichem Chemie Research Ltd

ViiV Healthcare Ltd

Viralytics Ltd

ViraTherapeutics GmbH

VLP Therapeutics LLC

WntResearch AB

X4 Pharmaceuticals Inc

Zestagen SA

Table of Contents

Table of Contents

Table of Contents 2

Introduction 11

Melanoma - Overview 12

Melanoma - Therapeutics Development 13

Melanoma - Therapeutics Assessment 71

Melanoma - Companies Involved in Therapeutics Development 103

Melanoma - Drug Profiles 230

Melanoma - Dormant Projects 1675

Melanoma - Discontinued Products 1701

Melanoma - Product Development Milestones 1705

Appendix 1721

List of Tables

List of Tables

Number of Products under Development for Melanoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Companies, H1 2017 (Contd..6), H1 2017

Products under Development by Companies, H1 2017 (Contd..7), H1 2017

Products under Development by Companies, H1 2017 (Contd..8), H1 2017

Products under Development by Companies, H1 2017 (Contd..9), H1 2017

Products under Development by Companies, H1 2017 (Contd..10), H1 2017

Products under Development by Companies, H1 2017 (Contd..11), H1 2017

Products under Development by Companies, H1 2017 (Contd..12), H1 2017

Products under Development by Companies, H1 2017 (Contd..13), H1 2017

Products under Development by Companies, H1 2017 (Contd..14), H1 2017

Products under Development by Companies, H1 2017 (Contd..15), H1 2017

Products under Development by Companies, H1 2017 (Contd..16), H1 2017

Products under Development by Companies, H1 2017 (Contd..17), H1 2017

Products under Development by Companies, H1 2017 (Contd..18), H1 2017

Products under Development by Companies, H1 2017 (Contd..19), H1 2017

Products under Development by Companies, H1 2017 (Contd..20), H1 2017

Products under Development by Companies, H1 2017 (Contd..21), H1 2017

Products under Development by Companies, H1 2017 (Contd..22), H1 2017

Products under Development by Companies, H1 2017 (Contd..23), H1 2017

Products under Development by Companies, H1 2017 (Contd..24), H1 2017

Products under Development by Companies, H1 2017 (Contd..25), H1 2017

Products under Development by Companies, H1 2017 (Contd..26), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017

Melanoma – Pipeline by 4P-Pharma SAS, H1 2017

Melanoma – Pipeline by 4SC AG, H1 2017

Melanoma – Pipeline by AB Science SA, H1 2017

Melanoma – Pipeline by AbbVie Inc, H1 2017

Melanoma – Pipeline by Abivax SA, H1 2017

Melanoma – Pipeline by Adaptimmune Therapeutics Plc, H1 2017

Melanoma – Pipeline by Aduro BioTech Inc, H1 2017

Melanoma – Pipeline by Advanced Cancer Therapeutics LLC, H1 2017

Melanoma – Pipeline by Affichem SA, H1 2017

Melanoma – Pipeline by Agenus Inc, H1 2017

Melanoma – Pipeline by AGV Discovery SAS, H1 2017

Melanoma – Pipeline by AIMM Therapeutics BV, H1 2017

Melanoma – Pipeline by Alethia Biotherapeutics Inc, H1 2017

Melanoma – Pipeline by Alkermes Plc, H1 2017

Melanoma – Pipeline by Altor BioScience Corp, H1 2017

Melanoma – Pipeline by Amgen Inc, H1 2017

Melanoma – Pipeline by Anavex Life Sciences Corp, H1 2017

Melanoma – Pipeline by Angimmune LLC, H1 2017

Melanoma – Pipeline by Antibe Therapeutics Inc, H1 2017

Melanoma – Pipeline by Antigen Express Inc, H1 2017

Melanoma – Pipeline by APEIRON Biologics AG, H1 2017

Melanoma – Pipeline by Apexigen Inc, H1 2017

Melanoma – Pipeline by Aphios Corp, H1 2017

Melanoma – Pipeline by Apogenix GmbH, H1 2017

Melanoma – Pipeline by Aposense Ltd, H1 2017

Melanoma – Pipeline by Aptose Biosciences Inc, H1 2017

Melanoma – Pipeline by ARMO Biosciences Inc, H1 2017

Melanoma – Pipeline by Array BioPharma Inc, H1 2017

Melanoma – Pipeline by Asana BioSciences LLC, H1 2017

Melanoma – Pipeline by Astellas Pharma Inc, H1 2017

Melanoma – Pipeline by Astex Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by AstraZeneca Plc, H1 2017

Melanoma – Pipeline by Aurigene Discovery Technologies Ltd, H1 2017

Melanoma – Pipeline by Autotelic Inc, H1 2017

Melanoma – Pipeline by Basilea Pharmaceutica Ltd, H1 2017

Melanoma – Pipeline by Batu Biologics Inc, H1 2017

Melanoma – Pipeline by Bayer AG, H1 2017

Melanoma – Pipeline by BeiGene (Beijing) Co Ltd, H1 2017

Melanoma – Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017

Melanoma – Pipeline by Bellicum Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by BerGenBio ASA, H1 2017

Melanoma – Pipeline by Bio-Cancer Treatment International Ltd, H1 2017

Melanoma – Pipeline by Biocad, H1 2017

Melanoma – Pipeline by Biogazelle NV, H1 2017

Melanoma – Pipeline by BioLineRx Ltd, H1 2017

Melanoma – Pipeline by Bioncotech Therapeutics SL, H1 2017

Melanoma – Pipeline by Bionomics Ltd, H1 2017

Melanoma – Pipeline by BioNTech AG, H1 2017

Melanoma – Pipeline by Biothera Pharmaceutical Inc, H1 2017

Melanoma – Pipeline by Biovista Inc, H1 2017

Melanoma – Pipeline by Boehringer Ingelheim GmbH, H1 2017

Melanoma – Pipeline by Boston Biomedical Inc, H1 2017

Melanoma – Pipeline by Bristol-Myers Squibb Company, H1 2017

Melanoma – Pipeline by Calithera Biosciences Inc, H1 2017

Melanoma – Pipeline by Can-Fite BioPharma Ltd, H1 2017

Melanoma – Pipeline by CCRP Therapeutics GmbH, H1 2017

Melanoma – Pipeline by Celgene Corp, H1 2017

Melanoma – Pipeline by Celldex Therapeutics Inc, H1 2017

Melanoma – Pipeline by Celprogen Inc, H1 2017

Melanoma – Pipeline by Celyad SA, H1 2017

Melanoma – Pipeline by Checkmate Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Chipscreen Biosciences Ltd, H1 2017

Melanoma – Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017

Melanoma – Pipeline by Cipher Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Corvus Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by CytomX Therapeutics Inc, H1 2017

Melanoma – Pipeline by Cytori Therapeutics Inc, H1 2017

Melanoma – Pipeline by Cytune Pharma SAS, H1 2017

Melanoma – Pipeline by CyTuVax BV, H1 2017

Melanoma – Pipeline by CZ BioMed Corp, H1 2017

Melanoma – Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Melanoma – Pipeline by Deciphera Pharmaceuticals LLC, H1 2017

Melanoma – Pipeline by DEKK-TEC Inc, H1 2017

Melanoma – Pipeline by Dicerna Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Dynavax Technologies Corp, H1 2017

Melanoma – Pipeline by Eisai Co Ltd, H1 2017

Melanoma – Pipeline by Eli Lilly and Company, H1 2017

Melanoma – Pipeline by Elsalys Biotech SAS, H1 2017

Melanoma – Pipeline by Ensol Biosciences Inc, H1 2017

Melanoma – Pipeline by EntreChem SL, H1 2017

Melanoma – Pipeline by eTheRNA Immunotherapies NV, H1 2017

Melanoma – Pipeline by Exelixis Inc, H1 2017

Melanoma – Pipeline by Exicure Inc, H1 2017

Melanoma – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Melanoma – Pipeline by Faron Pharmaceuticals Oy, H1 2017

Melanoma – Pipeline by Galapagos NV, H1 2017

Melanoma – Pipeline by Galectin Therapeutics Inc, H1 2017

Melanoma – Pipeline by Genelux Corp, H1 2017

Melanoma – Pipeline by Genocea Biosciences Inc, H1 2017

Melanoma – Pipeline by Genzyme Corp, H1 2017

Melanoma – Pipeline by GlaxoSmithKline Plc, H1 2017

Melanoma – Pipeline by Gradalis Inc, H1 2017

Melanoma – Pipeline by GreenPeptide Co Ltd, H1 2017

Melanoma – Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017

Melanoma – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Melanoma – Pipeline by Heat Biologics Inc, H1 2017

Melanoma – Pipeline by Hemispherx Biopharma Inc, H1 2017

Melanoma – Pipeline by Histogen Inc, H1 2017

Melanoma – Pipeline by HitGen LTD, H1 2017

Melanoma – Pipeline by Horizon Pharma Plc, H1 2017

Melanoma – Pipeline by Humorigin Biotechnology Corp, H1 2017

Melanoma – Pipeline by Idera Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Ignyta Inc, H1 2017

Melanoma – Pipeline by Immodulon Therapeutics Ltd, H1 2017

Melanoma – Pipeline by Immune Design Corp, H1 2017

Melanoma – Pipeline by Immune Response BioPharma Inc, H1 2017

Melanoma – Pipeline by ImmunGene Inc, H1 2017

Melanoma – Pipeline by Immunocore Ltd, H1 2017

Melanoma – Pipeline by ImmunoGen Inc, H1 2017

Melanoma – Pipeline by Immupharma Plc, H1 2017

Melanoma – Pipeline by IMPACT Therapeutics Inc, H1 2017

Melanoma – Pipeline by Imugene Ltd, H1 2017

Melanoma – Pipeline by Incyte Corp, H1 2017

Melanoma – Pipeline by Infinity Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Innovation Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by InteRNA Technologies BV, H1 2017

Melanoma – Pipeline by Intezyne Technologies Inc, H1 2017

Melanoma – Pipeline by IO Biotech ApS, H1 2017

Melanoma – Pipeline by JHL Biotech Inc, H1 2017

Melanoma – Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017

Melanoma – Pipeline by Johnson & Johnson, H1 2017

Melanoma – Pipeline by K-Stemcell Co Ltd, H1 2017

Melanoma – Pipeline by KaloBios Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Kancera AB, H1 2017

Melanoma – Pipeline by Karyopharm Therapeutics Inc, H1 2017

Melanoma – Pipeline by Kite Pharma Inc, H1 2017

Melanoma – Pipeline by Leap Therapeutics Inc, H1 2017

Melanoma – Pipeline by Lentigen Technology Inc, H1 2017

Melanoma – Pipeline by Lindis Biotech GmbH, H1 2017

Melanoma – Pipeline by Lion Biotechnologies Inc, H1 2017

Melanoma – Pipeline by Lipotek Pty Ltd, H1 2017

Melanoma – Pipeline by Lixte Biotechnology Holdings Inc, H1 2017

Melanoma – Pipeline by Loxo Oncology Inc, H1 2017

Melanoma – Pipeline by Lupin Ltd, H1 2017

Melanoma – Pipeline by Lytix Biopharma AS, H1 2017

Melanoma – Pipeline by MabVax Therapeutics Holdings Inc, H1 2017

Melanoma – Pipeline by MacroGenics Inc, H1 2017

Melanoma – Pipeline by Magnus Life Ltd, H1 2017

Melanoma – Pipeline by MaxiVAX SA, H1 2017

Melanoma – Pipeline by MediaPharma Srl, H1 2017

Melanoma – Pipeline by Medicenna Therapeutics Corp, H1 2017

Melanoma – Pipeline by MedImmune LLC, H1 2017

Melanoma – Pipeline by MELEMA Pharma GmbH, H1 2017

Melanoma – Pipeline by Merck & Co Inc, H1 2017

Melanoma – Pipeline by Merck KGaA, H1 2017

Melanoma – Pipeline by Millennium Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Molecular Templates Inc, H1 2017

Melanoma – Pipeline by Moleculin Biotech Inc, H1 2017

Melanoma – Pipeline by Morphotek Inc, H1 2017

Melanoma – Pipeline by NantKwest Inc, H1 2017

Melanoma – Pipeline by Nektar Therapeutics, H1 2017

Melanoma – Pipeline by Neonc Technologies Inc, H1 2017

Melanoma – Pipeline by Nerviano Medical Sciences Srl, H1 2017

Melanoma – Pipeline by Neumedicines Inc, H1 2017

Melanoma – Pipeline by NewLink Genetics Corp, H1 2017

Melanoma – Pipeline by NormOxys Inc, H1 2017

Melanoma – Pipeline by Northwest Biotherapeutics Inc, H1 2017

Melanoma – Pipeline by Novartis AG, H1 2017

Melanoma – Pipeline by Novogen Ltd, H1 2017

Melanoma – Pipeline by Omeros Corp, H1 2017

Melanoma – Pipeline by Oncology Research International Ltd, H1 2017

Melanoma – Pipeline by Oncolys BioPharma Inc, H1 2017

Melanoma – Pipeline by Oncolytics Biotech Inc, H1 2017

Melanoma – Pipeline by OncoNOx ApS, H1 2017

Melanoma – Pipeline by OncoSec Medical Inc, H1 2017

Melanoma – Pipeline by OncoTartis Inc, H1 2017

Melanoma – Pipeline by Oncovir Inc, H1 2017

Melanoma – Pipeline by Onxeo SA, H1 2017

Melanoma – Pipeline by Opsona Therapeutics Ltd, H1 2017

Melanoma – Pipeline by Orega Biotech SAS, H1 2017

Melanoma – Pipeline by OSE Immunotherapeutics, H1 2017

Melanoma – Pipeline by Pacific Northwest Biotechnology LLC, H1 2017

Melanoma – Pipeline by Patrys Ltd, H1 2017

Melanoma – Pipeline by PepVax Inc, H1 2017

Melanoma – Pipeline by Peregrine Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Pfizer Inc, H1 2017

Melanoma – Pipeline by Pharmicell Co Ltd, H1 2017

Melanoma – Pipeline by Pharminox Ltd, H1 2017

Melanoma – Pipeline by Pharmis Biofarmaceutica Lda, H1 2017

Melanoma – Pipeline by Philogen SpA, H1 2017

Melanoma – Pipeline by PinCell srl, H1 2017

Melanoma – Pipeline by Pivotal BioSciences Inc, H1 2017

Melanoma – Pipeline by Plexxikon Inc, H1 2017

Melanoma – Pipeline by Polaris Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Polyplus-Transfection SA, H1 2017

Melanoma – Pipeline by Prima BioMed Ltd, H1 2017

Melanoma – Pipeline by Primevax Immuno Oncology Inc, H1 2017

Melanoma – Pipeline by Propanac Biopharma Inc, H1 2017

Melanoma – Pipeline by Provectus Biopharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Provenance Biopharmaceuticals Corp, H1 2017

Melanoma – Pipeline by Qu Biologics Inc, H1 2017

Melanoma – Pipeline by Rafael Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Reata Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Recepta Biopharma SA, H1 2017

Melanoma – Pipeline by Recombio SL, H1 2017

Melanoma – Pipeline by Regeneron Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Rexahn Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Rgenix Inc, H1 2017

Melanoma – Pipeline by Rubicon Biotechnology Inc, H1 2017

Melanoma – Pipeline by RXi Pharmaceuticals Corp, H1 2017

Melanoma – Pipeline by Sanofi, H1 2017

Melanoma – Pipeline by SATT North SAS, H1 2017

Melanoma – Pipeline by Scancell Holdings Plc, H1 2017

Melanoma – Pipeline by SilaGene Inc, H1 2017

Melanoma – Pipeline by Sillajen Biotherapeutics, H1 2017

Melanoma – Pipeline by SolaranRx Inc, H1 2017

Melanoma – Pipeline by Sorrento Therapeutics Inc, H1 2017

Melanoma – Pipeline by Spotlight Innovation Inc, H1 2017

Melanoma – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Melanoma – Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017

Melanoma – Pipeline by Susavion Biosciences Inc, H1 2017

Melanoma – Pipeline by SuviCa Inc, H1 2017

Melanoma – Pipeline by Syndax Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Synthon Holdings BV, H1 2017

Melanoma – Pipeline by Syntrix Biosystems Inc, H1 2017

Melanoma – Pipeline by Tactiva Therapeutics LLC, H1 2017

Melanoma – Pipeline by Taiga Biotechnologies Inc, H1 2017

Melanoma – Pipeline by Taiwan Liposome Company Ltd, H1 2017

Melanoma – Pipeline by Takara Bio Inc, H1 2017

Melanoma – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Melanoma – Pipeline by Takis Srl, H1 2017

Melanoma – Pipeline by Targovax ASA, H1 2017

Melanoma – Pipeline by TC BioPharm Ltd, H1 2017

Melanoma – Pipeline by Theravectys SA, H1 2017

Melanoma – Pipeline by Tikcro Technologies Ltd, H1 2017

Melanoma – Pipeline by TILT Biotherapeutics Ltd, H1 2017

Melanoma – Pipeline by Tiltan Pharma Ltd, H1 2017

Melanoma – Pipeline by Tocagen Inc, H1 2017

Melanoma – Pipeline by TREAT U SA, H1 2017

Melanoma – Pipeline by TVAX Biomedical Inc, H1 2017

Melanoma – Pipeline by UbiVac LLC, H1 2017

Melanoma – Pipeline by Ultimovacs AS, H1 2017

Melanoma – Pipeline by UNC Health Care, H1 2017

Melanoma – Pipeline by Vaccibody AS, H1 2017

Melanoma – Pipeline by Vascular Biogenics Ltd, H1 2017

Melanoma – Pipeline by Vault Pharma Inc, H1 2017

Melanoma – Pipeline by Vaxenta Biotechnologies, H1 2017

Melanoma – Pipeline by Vichem Chemie Research Ltd, H1 2017

Melanoma – Pipeline by ViiV Healthcare Ltd, H1 2017

Melanoma – Pipeline by Viralytics Ltd, H1 2017

Melanoma – Pipeline by ViraTherapeutics GmbH, H1 2017

Melanoma – Pipeline by VLP Therapeutics LLC, H1 2017

Melanoma – Pipeline by WntResearch AB, H1 2017

Melanoma – Pipeline by X4 Pharmaceuticals Inc, H1 2017

Melanoma – Pipeline by Zestagen SA, H1 2017

Melanoma – Dormant Projects, H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..1), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..2), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..3), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..4), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..5), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..6), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..7), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..8), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..9), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..10), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..11), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..12), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..13), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..14), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..15), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..16), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..17), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..18), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..19), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..20), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..21), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..22), H1 2017

Melanoma – Dormant Projects, H1 2017 (Contd..23), H1 2017

Melanoma – Discontinued Products, H1 2017

Melanoma – Discontinued Products, H1 2017 (Contd..1), H1 2017

Melanoma – Discontinued Products, H1 2017 (Contd..2), H1 2017

Melanoma – Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures

List of Figures

Number of Products under Development for Melanoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports